In the context of this trial, and this case report, the small dataset behind CURATE.AI operations not only enabled personalized treatment of the patient with a rare disease but also facilitated dynamic treatment adaptation to his unique circumstances and systemic changes such as elevated IgM levels post-COVID-19. This evidence concerns the gene CD40LG and COVID-19.